Evidence map›Paper›PMID 35747002›Full record

ArticleCureus2022

A Case Series of SARS-CoV-2 Omicron Variant in Patients With Acute Leukemia.

Elrazi A Ali, Mohammed A Alamin, Mohammad Abu-Tineh, Khalid Ahmed, Awni Alshurafa, Waail Rozi, Mohamed A Yassin

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Elrazi A AliInternal Medicine, Hamad Medical Corporation, Doha, QAT.
Mohammed A AlaminInternal Medicine, Hamad Medical Corporation, Doha, QAT.
Mohammad Abu-TinehHematology, Hamad Medical Corporation, Doha, QAT.
Khalid AhmedHematology, Hamad Medical Corporation, Doha, QAT.
Awni AlshurafaHematology, Hamad Medical Corporation, Doha, QAT.
Waail RoziInternal Medicine, Hamad Medical Corporation, Doha, QAT.
Mohamed A YassinHematology, Hamad General Hospital, Doha, QAT.
Hamad Medical Corporation · QAHamad General Hospital · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) is a respiratory viral illness caused by coronavirus 2 (SARS-CoV-2). The disease often presents with non-specific symptoms, including fever, and fatigue, usually associated with respiratory symptoms (eg., cough) and other systemic involvement. The primary strategy to prevent transmission and reduce the disease severity of the SARS-CoV-2 infection is through vaccination. However, the virus had shown significant changes and mutations that resulted in the emergence of different strains. Each strain varies in its virulence, disease severity, and the body's immune system response. Previous reports showed that the Omicron variant causes mild disease. Little is known about the effect of Omicron in patients with acute leukemia. We present three patients with acute leukemia who had an infection with the Omicron variant of the SARS-CoV-2 virus.

Indexed as

acute leukemiaacute myeloid leukemia (aml)covid-19omicron variantsars-cov-2

Identifiers

PMID35747002
PMCPMC9212524
OpenAlexW4281262982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.